Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating)’s share price traded up 8.6% on Friday . The stock traded as high as $9.11 and last traded at $9.11. 64,605 shares were traded during mid-day trading, a decline of 98% from the average session volume of 2,942,308 shares. The stock had previously closed at $8.39.
Several research analysts recently weighed in on the company. The Goldman Sachs Group assumed coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating for the company. StockNews.com initiated coverage on Amicus Therapeutics in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, SVB Leerink lowered their price target on Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, February 24th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.00.
The firm has a market capitalization of $2.59 billion, a PE ratio of -9.52 and a beta of 1.41. The company has a quick ratio of 3.81, a current ratio of 4.00 and a debt-to-equity ratio of 1.63. The firm has a 50-day moving average price of $7.72 and a 200 day moving average price of $9.10.
In other Amicus Therapeutics news, CEO John F. Crowley sold 21,814 shares of the firm’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $8.00, for a total value of $174,512.00. Following the sale, the chief executive officer now directly owns 944,153 shares in the company, valued at $7,553,224. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ellen Rosenberg sold 11,018 shares of the firm’s stock in a transaction on Thursday, April 7th. The shares were sold at an average price of $9.06, for a total value of $99,823.08. Following the completion of the sale, the insider now owns 302,952 shares in the company, valued at $2,744,745.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,392 shares of company stock worth $487,754. Insiders own 2.50% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. First Horizon Advisors Inc. raised its stake in Amicus Therapeutics by 155.7% in the fourth quarter. First Horizon Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 1,776 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Amicus Therapeutics by 1,173.1% during the fourth quarter. Parallel Advisors LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 3,097 shares in the last quarter. Dark Forest Capital Management LP increased its position in shares of Amicus Therapeutics by 1,967.5% during the third quarter. Dark Forest Capital Management LP now owns 4,838 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 4,604 shares in the last quarter. Advisor Group Holdings Inc. increased its position in shares of Amicus Therapeutics by 30.4% during the fourth quarter. Advisor Group Holdings Inc. now owns 9,516 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 2,217 shares in the last quarter. Finally, Fieldpoint Private Securities LLC increased its position in shares of Amicus Therapeutics by 44.5% during the fourth quarter. Fieldpoint Private Securities LLC now owns 10,270 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 3,161 shares in the last quarter.
About Amicus Therapeutics (NASDAQ:FOLD)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- The Analysts Upgrade… Retail Stocks?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.